Welcome to BioSeeker Group!

Triple Analysis: Lymphoma, Angiogenesis and Cancer Vaccines

Additional Information

Published Date Mar 19, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 3665
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Lymphoma, Angiogenesis and Cancer Vaccines in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in Lymphoma and by the two mechanism/target/effect areas of Angiogenesis and Cancer Vaccines.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Lymphoma, Angiogenesis and Cancer Vaccines.

    To find out more about Triple Analysis: Lymphoma, Angiogenesis and Cancer Vaccines, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Lymphoma, Angiogenesis and Cancer Vaccines is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in Lymphoma and by the two mechanism/target/effect areas of Angiogenesis and Cancer Vaccines. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Lymphoma
The lymphoma report part comprises defined and up to date development strategies for 282 lymphoma drugs within the portfolio of 154 investigators, from Ceased to Marketed. This part extensively analyses their 181 identified drug targets, organized into 173 drug target strategies, and assesses them in eight different compound strategies and and five subindications of lymphoma.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market

Part II: Angiogenesis
The angiogenesis affecting cancer drug report part comprises defined and up to date development strategies for 252 drugs in oncology within the portfolio of 151 companies world-wide, from Ceased to Marketed. The report extensively analyses their 177 identified drug targets, organized into 170 drug target strategies, and assesses them in 70 cancer indications.
This part is based on the following publication:
Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

Part III: Cancer Vaccines
The cancer vaccine drug report part comprises defined and up to date development strategies for 196 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 137 identified drug targets, organized into 114 drug target strategies, and assesses them in 52 cancer indications.
This part is based on the following publication:
Cancer Vaccines: From First-in-Class to Best-in-Class?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Lymphoma
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Lymphoma Drugs for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 30-387
7 Emerging New Products to Established Ones: Drug Target Strategies of Lymphoma Drugs by their Highest Stage of Development (173 Drug Target Strategies and 282 Lymphoma Drugs) 388-596
8 Compound Strategies at Work: Competitive Benchmarking of Lymphoma Drugs by Compound Strategy (8 Compound Strategies) 597-636
9 Selecting Subindication for Lymphoma Drugs (Five Subindications of Lymphoma) 637-657
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lymphoma Drug Pipeline by Investigator (152 Companies) 658-938
11 Disclaimer 939
12 Drug Index 940
13 Company Index 948
Figures: Includes 6 Figures
Tables: Includes 222 Tables
Total Number of Pages: 954

Part II: Angiogenesis
5.1 The Scope of this Report 37
6 Consider the Therapeutic Target Among Angiogenesis Affecting Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (177 Drug Targets) 41-421
7 Emerging New Products to Established Ones: Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology by their Highest Stage of Development (170 Drug Target Strategies and 252 Drugs) 424-666
8 Compound Strategies at Work: Competitive Benchmarking of Angiogenesis Affecting Cancer Drugs by Compound Strategy (7 Compound Strategies) 667-709
9 Selecting Indication for Angiogenesis Affecting Drugs in Oncology (70 Cancer Indications) 710-848
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator (151 Investigators and 252 Drugs) 849-1685
12 Drug Index 1687
13 Company Index 1697
Figures: Includes 7 Figures
Tables: Includes 310 Tables
Total Number of Pages: 1,704

Part III: Cancer Vaccines
5.1 The Scope of this Report 28
6 Consider the Therapeutic Target Among Cancer Vaccine Drugs for the Highest Therapeutic Outcome and Return on Investment (137 Drug Targets) 32-245
7 First-in-Class and Me-too Analysis of Cancer Vaccine Drugs (114 Drug Target Strategies and 196 Drugs) 246-262
8 Is First-in-Class the Best-in-Class? 263-386
9 Compound Strategies at Work: Competitive Benchmarking of Cancer Vaccine Drugs by Compound Strategy (7 Compound Strategies) 387-413
10 The Competition Through Close Mechanistic Approximation of Cancer Vaccine Drugs 414-416
11 Selecting Indications for Cancer Vaccine Drugs (52 Cancer Indications) 417-492
12 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Vaccine Drug Pipeline by Company (114 Companies and 196 Drugs) 493-993
13 Disclaimer 994
Figures: Includes 5 Figures
Tables: Includes 239 Tables
Total Number of Pages: 1,007

This Report Includes the Following Companies:
4SC
Abbott
Abiogen
AC Immune
Acceleron Pharma
Access
Active Biotech
Adaptimmune
Adherex
Advantagene
Advaxis
Advenchen
AEgera
AEterna Zentaris
Affimed Therapeutics
Agennix
Agenus
Aida Pharmaceuticals
Alfa Wassermann
Alfacell
Allos Therapeutics
Alnylam
AlphaVax
Ambit Biosciences
Ambrilia Biopharma
Amgen
Amphora
Angiogen
Angiogenex
Angstrom Pharmaceuticals
Ansaris
Antisoma
Anza Therapeutics
Apricus Biosciences
Arana Therapeutics
Argos Therapeutics
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Ascenta Therapeutics
Astellas
Astex Therapeutics
AstraZeneca
Attenuon
Austrianova
AVEO
Bavarian Nordic
Bayer
Bellicum Pharmaceuticals
Benitec
BioAlliance Pharma
BioAxone
Biocad
Biocon
BioCryst Pharmaceuticals
Biogen Idec
Biolex
BioNTech
BioSante
Biostar
BioVex
Boehringer Ingelheim
Bolder BioTechnology
Borean Pharma
BreakThrough Therapeutics
Bristol-Myers Squibb
BTG
Cancer Advances
Cancer Research Technology
CDG Therapeutics
Celecure
Celera
Celgene
Cell Therapeutics
CellCeutix
Celldex Therapeutics
Cellmid
Celltrion
Center of Molecular Immunology
Cephalon
CG Therapeutics
ChemoCentryx
Chemokine Therapeutics
China Sky One Medical
Choongwae
Circadian Technologies
Cornerstone Pharmaceuticals
Cosmo Pharmaceuticals
CreaGene
CSL
Cue Biotech
CureTech
CureVac
Curis
Cyclacel
Cylene Pharmaceuticals
CytImmune Sciences
Cytochroma
Cytokinetics
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Deciphera Pharmaceuticals
Dendreon
DeveloGen
Dr Reddy’s
Dyax
Dynavax Technologies
Eisai
Eleos
Eli Lilly
Emergent BioSolutions
EntreMed
Enzon
Epeius Biotechnologies
EpiCept
Epizyme
Etubics
Exelixis
ExonHit Therapeutics
Favrille
Five Prime Therapeutics
Forma Therapeutics
Galena Biopharma
GammaCan
Gemin X Biotechnologies
Genencor
Genentech
Generex
Genmab
GenOdyssee Pharmaceuticals
GenPat77
Genta
Genticel
Genzyme
Geron
Gilead Sciences
GlaxoSmithKline
Gliknik
GlobeImmune
GlycoGenesys
Gradalis
Green Cross
Hayashibara
Heat Biologics
Heber Biotec
HemaQuest
Hemispherx Biopharma
Hoffmann-La Roche
Human Genome Sciences
Hy BioPharma
Ichor Medical Systems
Idera Pharmaceuticals
IGF Oncology
ImClone Systems
immatics biotechnologies
ImmunoCellular Therapeutics
ImmunoFrontier
ImmunoGen
Immunomedics
Immunotope
Immunovaccine
ImmuPharma
Inex
Innate Pharma
InNexus Biotechnology
Inovio
Intas Biopharmaceuticals
Intracel
Introgen Therapeutics
ISA Pharmaceuticals
Isis Pharmaceuticals
Italfarmaco
Jennerex Biotherapeutics
Johnson & Johnson
KAEL-GemVax
KAI Pharmaceuticals
Karus Therapeutics
Kinex
Kirin Pharma
Kissei
Kringle Pharma
Kyowa Hakko Kirin
Lee’s Pharmaceutical
Leo
LG Life Sciences
Ligand
Lipotek
Lorus Therapeutics
MacroGenics
Mannkind
MAT Biopharma
Meda
MediGene
MedImmune
Menarini
Merck & Co
Merck KGaA
Mersana Therapeutics
MethylGene
Micromet
MolMed
Mologen
Momotaro-Gene
Morvus Technology
Nektar Therapeutics
Nemod Biotherapeutics
Neovacs
Nereus Pharmaceuticals
Nerviano Medical Sciences
NewSouth Innovations
NIH
Non-industrial source
Northwest Biotherapeutics
Novartis
NovaRx
Novelix
Noxxon
Nycomed Pharma
Oasmia
OncoMune
Onconova
OncoTherapy Science
Oncothyreon
Oncovir
Onyvax
Orchestra Therapeutics
OSI Pharmaceuticals
Otsuka
Oxford BioMedica
OXiGENE
Pepscan Therapeutics
Peptagen
PepTx
Peregrine Pharmaceuticals
Pfizer
Pharmacopeia
Pharmacyclics
PharmaForm
PharmaMar
Pharmexa
Pharminox
Philogen
PhiloGene
Pierre Fabre
Piramal
Plexxikon
Portola Pharmaceuticals
Progen
Progenics Pharmaceuticals
ProNAi Therapeutics
Protein Sciences
Protgen
Protherics
PTC Therapeutics
Radient Pharmaceuticals
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Reliance Life Sciences
responsif
Rexahn
Rigel
Sanofi
Sanofi-Aventis
Santaris Pharma
Sarepta Therapeutics
SBIO
Scancell
SciClone Pharmaceuticals
Seattle Genetics
Selvita
Semafore Pharmaceuticals
Shionogi
Shire
Simcere Pharmaceuticals
Spear Therapeutics
SRI International
Stainwei Biotech
SuperGen
SuppreMol
Switch Pharma
Synageva BioPharma
SynDevRx
Taiho
Takeda
Tapestry Pharmaceuticals
TapImmune
Tau Therapeutics
Tekmira Pharmaceuticals
Telik
TetraLogic Pharmaceuticals
Teva
Therion Biologics
ThromboGenics
Tigris Pharmaceuticals
Titan Pharmaceuticals
ToolGen
TopoTarget
Tracon Pharmaceuticals
Transgene
Trion Pharma
UCB
United Biomedical
Vaccinex
Vaxil BioTherapeutics
Vaximm
Vaxon Biotech
VBL Therapeutics
Vectura
VentiRx Pharmaceuticals
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
Viragen
Virionics
ViroMed
XBiotech
Xencor
Xerion
Yakult Honsha
Zenotech
Zensun
Zenyaku Kogyo
Zydus Cadila
A Shortlist of Drugs Included are:
131I-tositumomab
A6
abagovomab
ABT-510
ADXS11-001
AE-37
aflibercept
AGS-003
alemtuzumab
AMG-386
amrubicin hydrochloride
Angiozyme
ANZ-207
apatinib
ARQ-197
astuprotimut-r
atrasentan
Auto TAG vaccine
AVX-701
axitinib
belagenpumatucel-L
belinostat
bevacizumab
bexarotene
BIBF-1120
BMS-690514
bortezomib
BP-GMAX-CD1
brentuximab vedotin
brivanib alaninate
BV-NSCLC-001
CB-10-01
CDX-1307
cediranib
CG-201
cilengitide
cladribine
CreaVax-PC
CV-9103
CV-9201
CVac
DCVax-prostate
denileukin diftitox
DI-17E6
dovitinib lactate
E-75
E-7820
elliptinium acetate
emepepimut-S
endostatin
ENMD-2076
enzastaurin hydrochloride
epirubicin
everolimus
Exherin
foretinib
fosbretabulin tromethamine
galiximab
GI-4000
GliaAtak
GSK-2130579A
GT-111
GV-1001
GVAX
GVX-3322
HBP-347
Her-2/Neu peptides
Hi-8 MEL
HS-110
ibritumomab tiuxetan
icrucumab
ICT-107
imMucin
IMO-2055
inotuzumab ozogamicin
interferon (alpha)
interferon (alpha2b)
interferon (gamma)
interferon alfa-2b
interferon alpha-2b
interleukin-12
intetumumab
IPP-204106
irinotecan hydrochloride
ISA-P53-01
JI-101
JX-594
lenvatinib
linifanib
LY-2275796
MDX-1379
MGCD-265
MGN-1601
midostaurin
mitoxantrone
motesanib diphosphate
muparfostat (IV)
MVA-BN Her-2 vaccine
NGR-TNF
obinutuzumab
oblimersen sodium
ofatumumab
ON-01910
OncoVAX
Onyvax-105
OTS-102
p.DOM-WT1-37/p.DOM-WT1-126 DNA
paclitaxel
PancAtak
panobinostat
pazopanib hydrochloride
PCI-27483
pegdinetanib
PF-4856884
pixantrone
plitidepsin
poly-ICLC
polyclonal antibody stimulator
ponatinib
pralatrexate
ProstAtak
PROSTVAC
PSMA ADC
PTC-299
RAF-265
ramucirumab
razoxane
Reditux
regorafenib
Reximmune-C
rhIFN-alpha
ridaforolimus
rindopepimut
rintatolimod
rituximab
romidepsin
S-488410
SCIB-1
sipuleucel-T
sirolimus
sobuzoxane
sorafenib tosylate
SU-6668
sunitinib malate
Survivac
talactoferrin alfa
TAS-102
tasquinimod
TB-403
telatinib
temsirolimus
Tenarad
teniposide
TG-4010
thymalfasin
tipapkinogene sovacivec
tipifarnib
tivozanib
TRC-105
TroVax
vandetanib
velimogene aliplasmid
verpasep caltespen
vismodegib
vitespen
volociximab
VX-001
XL-184
XL-647
zanolimumab

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Lymphoma, Angiogenesis and Cancer Vaccines.
    To find out more about Triple Analysis: Lymphoma, Angiogenesis and Cancer Vaccines, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Lymphoma, Angiogenesis and Cancer Vaccines is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Leukemia, Pancreatic Cancer and Apoptosis
This triple analysis focuses on cancer drug development strategies in both Leukemia and Pancreatic Cancer and by the mechanism/target/effect of Apoptosis. Learn More


Triple Analysis: Colorectal Cancer, Lymphoma and Peptides
This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Lymphoma and by the compound strategy of Peptides. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Colorectal Cancer, Prostate Cancer and Angiogenesis
This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Prostate Cancer and by the mechanism/target/effect of Angiogenesis. Learn More


T Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update
BioSeeker Group have identified 355 companies plus partners who are today developing 469 T cell receptor pathway targeting drugs in 1756 developmental projects in cancer across 242 different targets. In addition, there are 7 suspended drugs and another 210 drugs where development has been ceased. Learn More